Ozempic (Semaglutide Injection, Diabetes + Kidney)

Ozempic (semaglutide up to 2 mg weekly) holds the most expansive FDA indications of any GLP-1, including glycemic control in type 2 diabetes, reduction of major adverse cardiovascular events, and, as of January 28, 2025, reduction of worsening kidney disease and cardiovascular death in type 2 diabetes patients with CKD. The Phase 3b FLOW trial demonstrated a 24% relative risk reduction in a composite of kidney disease worsening, end-stage kidney disease, and cardiovascular death, plus a 29% relative risk reduction in CV death—making it the only GLP-1 RA with a kidney protection indication. While not formally approved for weight management, it induces 5-10% weight reduction at 1-2 mg doses. At a monthly list price of $900-$1,000 without insurance, it provides a lower-cost entry into the GLP-1 class for millions compared to Wegovy, with better diabetes coverage.